^Bredenoord, Albert J. Lesogaberan, a GABAB agonist for the potential treatment of gastroesophageal reflux disease. IDrugs. 2009, 12 (9): 576–584. PMID 19697277.
^Alstermark; Amin, K; Dinn, SR; et al. Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors. Journal of Medicinal Chemistry. 2008, 51 (14): 4315–4320. PMID 18578471. doi:10.1021/jm701425k.
^Hans Rydholm, Christian von Corswant, Hans Denison, Jörgen M Jensen,Anders Lehmann, Magnus Ruth, Erik Söderlind, Ann Aurell-Holmberg. Reducing Adverse Effects During Drug Development: The Example of Lesogaberan and Paresthesia. Clinical Therapeutics. 2016, 38 (4): 946-960. PMID 26947796. doi:10.1016/j.clinthera.2016.02.012.
^Moaz M. Abdou, Rasha A. El-Saeed. Potential chemical transformation of phosphinic acid derivatives and their applications in the synthesis of drugs. Bioorganic Chemistry. 2019, 90: 103039. doi:10.1016/j.bioorg.2019.103039.